posted on 2015-04-23, 00:00authored byMassimiliano Beltramo, Vincent Robert, Mathieu Galibert, Jean-Baptiste Madinier, Philippe Marceau, Hugues Dardente, Caroline Decourt, Nicolas De Roux, Didier Lomet, Agnès
F. Delmas, Alain Caraty, Vincent Aucagne
New
potent and selective KISS1R agonists were designed using a combination
of rational chemical modifications of the endogenous neuropeptide
kisspeptin 10 (KP10). Improved resistance to degradation and presumably
reduced renal clearance were obtained by introducing a 1,4-disubstituted
1,2,3-triazole as a proteolysis-resistant amide mimic and a serum
albumin-binding motif, respectively. These triazololipopeptides are
highly potent full agonists of KISS1R and are >100 selective over
the closely related NPFF1R. When injected in ewes with a quiescent
reproductive system, the best compound of our series induced a much
prolonged increase of luteinizing hormone release compared to KP10
and increased follicle-stimulating hormone plasma concentration. Hence,
this KISS1R agonist is a new valuable pharmacological tool to explore
the potential of KP system in reproduction control. Furthermore, it
represents the first step to develop drugs treating reproductive system
disorders due to a reduced activity of the hypothalamo–pituitary–gonadal
axis such as delayed puberty, hypothalamic amenorrhea, and hypogonadotropic
hypogonadism.